Bortezomib-High Dose Melphalan Conditioning for the Treatment of MM Patients Undergoing ASCT

被引：0
|
作者：
Jimenez-Zepeda, Victor [1 ]
Duggan, Peter [1 ]
Neri, Paola [2 ]
Chaudhry, Ahsan [3 ]
Tay, Jason [4 ]
Luider, Joanne [5 ]
Bahlis, Nizar J. [2 ,6 ]
机构：
[1] Tom Baker Canc Clin, Dept Med Oncol & Hematol, Calgary, AB, Canada
[2] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada
[3] Tom Baker Canc Clin, Calgary, AB, Canada
[4] Univ Calgary Tom Baker Canc Ctr, Calgary, AB, Canada
[5] Alberta Hlth Services, Calgary, AB, Canada
[6] Univ Calgary, Calgary, AB, Canada
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.2273.2273
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2273
引用
收藏
页数：5
相关论文
共 50 条
  • [1] High Dose Intravenous Busulfan and Melphalan Followed By Bortezomib (BuMelVel) As Conditioning With Autologous Stem Cell Transplantation (ASCT) For Patients With Multiple Myeloma (MM)
    Sterrenberg, Danielle
    Stiff, Patrick J.
    Parthasarathy, Mala
    Go, Aileen
    Smith, Scott E.
    Rodriguez, Tulio E.
    BLOOD, 2013, 122 (21)
  • [2] Treatment of AL Amyloidosis with Two Cycles of Induction Therapy with Bortezomib and Dexamethasone Followed by Bortezomib-High Dose Melphalan Conditioning and Autologous Stem Cell Transplantation
    Sanchorawala, Vaishali
    Shelton, Anthony C.
    Brauneis, Dina
    Quillen, Karen
    Andrea, Nancy T.
    Sloan, John Mark
    Seldin, David C.
    BLOOD, 2012, 120 (21)
  • [3] High Dose Intravenous Busulfan (BU) and Melphalan (MEL) Followed by Bortezomib (BTZ) as Conditioning with Autologous Peripheral Blood Stem Cell Transplantation (ASCT) for Patients with Multiple Myeloma (MM)
    Rodriguez, Tulio E.
    Stiff, Patrick J.
    Smith, Scott E.
    Kaufman, Jonathan L.
    Lee, Mary
    Parthasarathy, Mala
    Earley, Zachary M.
    Lonial, Sagar
    Vesole, David H.
    BLOOD, 2010, 116 (21) : 582 - 582
  • [4] Autologous stem cell transplantation (ASCT) after conditioning therapy with intermediate dose melphalan, bortezomib,thalidomide, dexamethasone (MVTD) in relapsed multiple myeloma (MM) patients
    Scalzulli, P. R.
    Bodenizza, C.
    Carella, A. M.
    Dell'Olio, M.
    Falcone, A. P.
    Greco, M. M.
    La Sala, A.
    Mantuano, S.
    Melillo, L.
    Merla, E.
    Nobile, M.
    Sanpaolo, G.
    Valvano, M. R.
    Cascavilla, N.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 212 - 212
  • [5] Autologus stem cell transplantation (ASCT) conditioning therapy intermediate dose Melphalan, Bortezomib, Thalidomide, Dexamethasone (MVRO) in relapsed multiple myeloma (MM)
    Scalzulli, P. R.
    Bodenizza, C. A.
    Carella, A. M.
    Dell'Olio, M.
    Falcone, A. P.
    Greco, M. M.
    La Sala, A.
    Mantuano, S.
    Melillo, L.
    Merla, E.
    Nobile, M.
    Sanpaolo, G.
    Musto, P.
    Valvano, M. R.
    Cascavilla, N.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 437 - 437
  • [6] Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma
    Buadi, Francis K.
    Gertz, Morie A.
    Laplant, Betsy R.
    Halvorson, Alese
    Lacy, Martha Q.
    Hayman, Suzanne R.
    Dingli, David
    Kapoor, Prashant
    Gonsalves, Wilson I.
    Miceli, Teresa
    Brandes, Eva
    Stafford, Scott L.
    Martenson, James A.
    Hogan, William J.
    Kumar, Shaji K.
    BLOOD, 2016, 128 (22)
  • [7] Intermediate dose melphalan, Bortezomib, Thalidomide, Dexametasone (MVTD) conditioning therapy and ASCT in relapsed multiple myeloma patients: A single center experience
    Scalzulli, Polito Rosario
    Valvano, Maria Rosa
    Bodenizza, Carlo C.
    Carella, Angelo Michele
    Dell'Olio, Matteo M.
    Falcone, Antonietta A. P.
    Greco, Michele Mario
    La Sala, Antonio A.
    Mantuano, Francesco F. S.
    Melillo, Lorella L.
    Merla, Emanuela E.
    Nobile, Michele M.
    Sanpaolo, G. Sanpaolo
    Cascavilla, Nicola N.
    BLOOD, 2007, 110 (11) : 361B - 361B
  • [8] Change in antiemetic prophylaxis in patients with myeloma undergoing conditioning with high-dose melphalan
    Skagerlind, L.
    Liljeholm, M.
    Astrom, F.
    Lindkvist, U.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S491 - S491
  • [9] BORTEZOMIB AND HIGH-DOSE MELPHALAN AS A NOVEL CONDITIONING REGIMEN FOR PATIENTS WITH POEMS SYNDROME UNDERGOING AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
    Tang, X.
    Shi, X.
    Hu, X.
    Xue, S.
    Qiu, H.
    Han, Y.
    Yan, L.
    Zhou, H.
    Liu, Y.
    Gu, B.
    Sun, A.
    Wu, D.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (02) : S202 - S202
  • [10] Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Annyloidosis: Results of a Prospective Clinical Trial
    Sanchorawala, Vaishali
    Brauneis, Dina
    Shelton, Anthony C.
    Lo, Stephen
    Sun, Fangui
    Sloan, J. Mark
    Quillen, Karen
    Seldin, David C.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (08) : 1445 - 1451
12345